Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 31 | SFEBES2013 | Next issue

Society for Endocrinology BES 2013

Symposia

New Bone Biology – Is there life after RANK ligand?

ea0031s4.2 | New Bone Biology – Is there life after RANK ligand? | SFEBES2013

Inhibition of sclerostin in the treatment of osteoporosis

Papapoulos Socrates

During the past few years there have been important developments in the pharmacotherapy of osteoporosis. These developments were paralleled by significant progress in our understanding of the local regulation of bone metabolism. Studies of human and animal genetics led to identification of novel signaling pathways in bone cells, such as the Wnt signaling pathway, that provide targets for new bone building therapeutics for patients with osteoporosis. Fundamental for these devel...

ea0031s4.3 | New Bone Biology – Is there life after RANK ligand? | SFEBES2013

Parathyroid hormone-related protein as a potential treatment for osteoporosis

Esbrit Pedro

Osteoporosis is defined as low bone mineral density and/or poor bone microarchitecture associated with increased risk of fractures. This chronic disease mainly affects postmenopausal women, but also older men, being increasingly considered as an age-related morbidity. Chronic glucocorticoid therapy and diabetes mellitus are also concomittant causes of osteopenia in aging subjects. The fact that osteoporosis-related fractures accompany the increased life span imposes a major ch...